-
7/26/2019 Boston Scientific Jefferies 2016 HC Conference
1/14
Jefferies Healthcare ConferenceJune 7, 2016
-
7/26/2019 Boston Scientific Jefferies 2016 HC Conference
2/14
2 Boston ScientificJefferies Healthcare Conference, June 7, 2016
Safe harbor for forward-looking statements
This presentation contains forward-looking statements within the meaning of Section 27A of theSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking
statements may be identified by words like anticipate, expect, project, believe, plan,
estimate, intend and similar words. These forward-looking statements are based on our beliefs,
assumptions and estimates using information available to us at the time and are not intended to
be guarantees of future events or performance. If our underlying assumptions turn out to be
incorrect, or if certain risks or uncertainties materialize, actual results could differ materially from
the expectations and projections expressed or implied by our forward-looking statements.
Factors that may cause such differences can be found in our most recent Form 10-K and Forms
10-Q filed or to be filed with the Securities and Exchange Commission under the headings Risk
Factors and Safe Harbor for Forward-Looking Statements. Accordingly, you are cautioned notto place undue reliance on any of our forward-looking statements. We disclaim any intention or
obligation to publicly update or revise any forward-looking statements to reflect any change in our
expectations or in events, conditions, or circumstances on which they may be based, or that may
affect the likelihood that actual results will differ from those contained in the forward-looking
statements.
-
7/26/2019 Boston Scientific Jefferies 2016 HC Conference
3/14
3 Boston ScientificJefferies Healthcare Conference, June 7, 2016
For reconciliations of non-GAAP financial measures used in these presentations to the mostdirectly comparable GAAP figures, please refer to the Investor Relations section of our website at
www.bostonscientific.com. Footnotes referenced in this presentation can be found on slide 14.
Disclaimers
http://www.bostonscientific.com/http://www.bostonscientific.com/ -
7/26/2019 Boston Scientific Jefferies 2016 HC Conference
4/14
4 Boston ScientificJefferies Healthcare Conference, June 7, 2016
BSX: What to expect from us
Consistently delivering on and exceeding financial goals1,2
Strong culture fostering innovation and a WINNING SPIRIT
2015: 5% organicgrowth, +210bps adj. OM, 23% adj. EPS growth ex FX
Q1:16: 8% organic growth, +260bps adj. OM, 41% adj. EPS growth ex FX
Transforming patients lives and leading in large global markets
Entering faster growth segments, driving category leadership
Building emerging markets scale and capabilities
Launching innovative new product cycle in 2016
Driving consistent organic revenue growth with a long runway
Leading globally: More to come in 2017-2018 and beyond
Launching into large, high growth markets with meaningful innovation
Creating value: MSD rev. growth + adj. OM expansion = DD adj. EPS growth ex FX
See slide 14 for footnotes
-
7/26/2019 Boston Scientific Jefferies 2016 HC Conference
5/14
5 Boston ScientificJefferies Healthcare Conference, June 7, 2016
InterventionalCardiology
Neuromodulation
Endoscopy
Urology andPelvic Health
Rhythm ManagementCRM, Heart Failure Management, Electrophysiology
$2.0B, +7%
$501M, +8%
$693M, +36%
CRM $1.8B, +1% EP $233M, +9%
Boston Scientific at-a-glance
$904M, +13%
$1.3B, +6%
$100M+
PeripheralInterventions
2015 reported revenue, constant currency Y/Y growth
Structural Heart
See slide 14 for footnotes
-
7/26/2019 Boston Scientific Jefferies 2016 HC Conference
6/14
6 Boston ScientificJefferies Healthcare Conference, June 7, 2016
Strong execution: Performance since 2012
Operational Revenue
Growth1,3Adj. Operating Margin2 Adj. EPS Growth2
Sales growth acceleration~500 bps adj. OM
expansionDouble-digit adj. EPS
growth ex FX
17.8%
18.9%
20.2%
22.3%
2012 2013 2014 2015
11%
15%
2012 2013 2014 2015
$7.4B
-3%
5%
2012 2013 2014 2015
11%
4%
Excludes foreign exchange impact(~$0.10 in 2015)
Includes foreign exchange impact
Operational revenue growth
Organic revenue growth
-2%
8%
6%
$7.4B
2%
$7.1B
$7.2B
**Adjusted for estimated impact of Medical Device Tax(~100bps), based on actual 2013 impact
**
See slide 14 for footnotes
23%
-
7/26/2019 Boston Scientific Jefferies 2016 HC Conference
7/147 Boston ScientificJefferies Healthcare Conference, June 7, 2016
STRENGTHEN
Category
Leadership
Strategic imperatives align execution
A preferred
leader & gaining
share in large
global segments
New commercial
capabilities to
lead in dynamic
markets
Adjusted
operating margin
target of 25%+
by 2017
Grow emerging
markets +500bps
as % total sales
2012-2017
Accelerate
growth &
diversify into
faster segments
DEVELOP
Key
Capabilities
FUND
the Journey
to Fuel Growth
DRIVE
Global
Expansion
EXPAND into
High Growth
Adjacencies
-
7/26/2019 Boston Scientific Jefferies 2016 HC Conference
8/148 Boston ScientificJefferies Healthcare Conference, June 7, 2016
------- Estimated market* -------
Business2015Size
2015Growth
20152020Growth
Investing in Faster Growth Segments
Endoscopy $3B 4% 4-6% Visualization, pulmonary therapies, endo ultrasound
Urology andPelvic Health
$3B 4% 4-6% Stone, BPH, ED, visualization, international
Neuromodulation $2B 5% 5-7% Severe pain, Parkinson's, OAB, international
CRM $10B 2% 0-2% S-ICD & leadless solutions, HF diagnostic solutions
Electrophysiology $3B 14% 10-15% Atrial fibrillation, mapping & navigation
Peripheral $4B 4% 4-6%Drug-eluting SFA, atherectomy, oncology, liver cancer
IC (ex SH) $8B 1% 0-3% Complex PCI, FFR, & bioresorbable technologies
Structural Heart $1.8B 35% 15-20% TAVR, LAAC, mitral
WW Total ~$35B ~3-4%
* Market size and growth rates at constant currency and are BSX internal estimates
Market outlook and investment focus
~3-6%
-
7/26/2019 Boston Scientific Jefferies 2016 HC Conference
9/149 Boston ScientificJefferies Healthcare Conference, June 7, 2016
EM +12% FY15,
+21% Q1:16
operational revenue3
China +20%
operational revenue3
Est. EM $1B in 2016
Est. EM 12% of
mix in 2016
(vs. 8% in 2012)
Strong team
Expanded
distribution
Product
registrations
R&D & training
centers
China JV
(Frankenman)
Driving global expansion
U.S.52%(+9%)
Europe22%(+8%)
AMEA20%
(+7%)
LACA 6%(+7%)
Global revenue mix
2015---------------- Emerging Markets ----------------
Growth highlights Growth drivers
Operational Revenue3,4,5
See slide 14 for footnotes
-
7/26/2019 Boston Scientific Jefferies 2016 HC Conference
10/1410 Boston ScientificJefferies Healthcare Conference, June 7, 2016
Accretive newproducts
5-10% annualstandard costimprovements
Optimize plantnetworks
AMS benefit
Reduce SG&A
R&Dproductivity
Reduceadjacencydilution
Outsourcing/
offshoring
Lean businessinitiatives
AMS benefit
2012A* 2013A 2014A 2015A** Gross Margin OperatingExpenses
2017E
25%+
~+100bps
~+200bps
20.2%
18.9%
17.8%
Significant adjusted operating margin2expansion:Estimated +700bps from 2012-2017
22.3%
*Adjusted for estimated impact of Medical Device Tax (~100bps), based on actual 2013 impact
See slide 14 for footnotes
-
7/26/2019 Boston Scientific Jefferies 2016 HC Conference
11/1411 Boston ScientificJefferies Healthcare Conference, June 7, 2016
Accretive new
products
5-10% annual
standard cost
improvements
Optimize plantnetworks
AMS benefit
Reduce SG&A
R&D productivity
Reduceadjacencydilution
Outsourcing/offshoring
Lean businessinitiatives
AMS benefit
Accretive newproducts
5-10% annualstandard costimprovements
Optimize plantnetworks
Reduce SG&Aand adjacencydilution
R&D productivity
AMS benefit
Outsourcing/offshoring
2015A* Gross Margin OperatingExpense
Reductions
2017E OperatingMargin
Improvements
2020E
25%+
Adjusted OM expansion opportunities beyond 2017
22.3%
27-28%
~+100bps
~+200bps
~+200 to300bps
-
7/26/2019 Boston Scientific Jefferies 2016 HC Conference
12/14
12 Boston ScientificJefferies Healthcare Conference, June 7, 2016
1. Debt repayment
2. M&A in adjacent, high-growth markets
3. Maintain flexibility
Litigation / tax contingencies
Cash flow outlook, capital allocation priorities
2014A 2015A 2016E*
$1.26B
$1.3B+
~$1.5B
Strong Cash Flow
Adjusted FCF6: 20142016E
2016 Capital
Allocation Priorities
*2016E represents guidance issued on Q4:15 earnings call, 2/4/16See slide 14 for footnotes
-
7/26/2019 Boston Scientific Jefferies 2016 HC Conference
13/14
13 Boston ScientificJefferies Healthcare Conference, June 7, 2016
BSX: What to expect from us
Consistently delivering on and exceeding financial goals1,2
Strong culture fostering innovation and a WINNING SPIRIT
2015: 5% organicgrowth, +210bps adj. OM, 23% adj. EPS growth ex FX
Q1:16: 8% organic growth, +260bps adj. OM, 41% adj. EPS growth ex FX
Transforming patients lives and leading in large global markets
Entering faster growth segments, driving category leadership
Building emerging markets scale and capabilities
Launching innovative new product cycle in 2016
Driving consistent organic revenue growth with a long runway
Leading globally: More to come in 2017-2018 and beyond
Launching into large, high growth markets with meaningful innovation
Creating value: MSD rev. growth + adj. OM expansion = DD adj. EPS growth ex FX
See slide 14 for footnotes
-
7/26/2019 Boston Scientific Jefferies 2016 HC Conference
14/14
14 Boston ScientificJefferies Healthcare Conference, June 7, 2016
Footnotes
1: Organic revenue growth excludes the impact of sales from divested businesses, changes in foreigncurrency exchange rates and sales from the acquisitions of the interventional business of Bayer AG andthe American Medical Systems male urology portfolio over the prior year period.
2: Adjusted operating margin, and adjusted earnings per share are non-GAAP and exclude goodwill andother intangible asset impairment charges, acquisition and divestiture-related net charges, litigation-related charges, restructuring and restructuring-related charges, pension termination charges, discrete
tax items and amortization expense.
3: Operational revenue growth is at constant currency, and excludes divested businesses.
4: Percent of revenue shown on a constant currency basis.
5: LACA = Latin America and Canada; AMEA = Asia, Middle East , and Africa
6:Adjusted Free Cash Flow excludes any potential amounts related to acquisition-, divestiture- andlitigation-related items, significant tax audit settlements and restructuring and restructuring-related items.
For reconciliations of non-GAAP financial measures to the most directly comparable GAAPfigures, please refer to the Investor Relations section of our website at
www.bostonscientific.com.
http://www.bostonscientific.com/http://www.bostonscientific.com/